Advanced search
Publication Cover
Cancer Biology & Therapy Volume 22, 2021 - Issue 10-12
Submit an article Journal homepage
1,907
Views
2
CrossRef citations to date
0
Altmetric
Research Paper

Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer in vitro and in vivo

Jocelyn E. Raya Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA;b Division of Gynecologic Oncology, Fox Chase Cancer Center, Philadelphia, PA, USAView further author information
,
Marie D. Ralffa Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA;c MD/PhD Program, the Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USAORCID Iconhttps://orcid.org/0000-0003-2113-0974View further author information
ORCID Icon,
Aakash Jhaverid Master of Science in Biotechnology Program, the Warren Alpert Medical School, Brown University, Providence, RI, USA;e Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, RI, USA;f Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USAView further author information
,
Lanlan Zhoua Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA;e Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, RI, USA;f Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA;g Cancer Center at Brown University, the Warren Alpert Medical School, Brown University, Providence, RI, USAView further author information
,
David T. Dickera Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA;e Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, RI, USA;f Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USAView further author information
,
Eric A. Rossh Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, USAView further author information
&
Wafik S. El-Deirya Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Medical Oncology and Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, USA;e Joint Program in Cancer Biology, Brown University and the Lifespan Health System, Providence, RI, USA;f Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School, Brown University, Providence, RI, USA;g Cancer Center at Brown University, the Warren Alpert Medical School, Brown University, Providence, RI, USA;i Brown University and the Lifespan Cancer Institute, Providence, RI, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9577-8266View further author information
ORCID Icon show all
Pages 554-563 | Received 01 Jun 2021, Accepted 27 Jul 2021, Published online: 25 Oct 2021

References

  • Society AC Key statistics for endometrial cancer.
  • Lortet-Tieulent J, Ferlay J, Bray F, International Patterns JA. Trends in Endometrial Cancer Incidence, 1978-2013. J Natl Cancer Inst. 2018;110:354–361.
  • Francis SR, Ager BJ, Do OA, Huang YJ, Soisson AP, Dodson MK, Werner TL, Sause WT, Grant JD, Gaffney DK. Recurrent early stage endometrial cancer: patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019;154:38–44.
  • https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf NCCNCPGiOUNV.
  • Stein MN, Bertino JR, Kaufman HL, Mayer T. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017;23:4163–4169.
  • Allen JE, Crowder RN, El-Deiry WS. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent. PLoS One. 2015;10:e0143082.
  • Allen JE, Krigsfeld G, Mayes Pa, Patel L, Dicker DT, Patel AS. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Sci Transl Med. 2013;5:171ra17.
  • Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science. 1997;276:111–113.
  • Wu GS, Burns TF, McDonald ER, 3rd, Jiang W. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet. 1997;17:141–143.
  • ONC 201 in uterine cancer 8. 2018.pdf.
  • Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2alpha kinases. Sci Signal. 2016;9:ra18.
  • Ralff MD, Jhaveri A, Ray JE, Zhou L, Lev A, Campbell KS, Dicker DT, Ross EA, El-Deiry WS. TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic. Oncotarget. 2020; 3753–3769.
  • Fang Z, Wang J, Clark LH, Sun W. ONC201 demonstrates anti-tumorigenic and anti-metastatic activity in uterine serous carcinoma in vitro. Am J Cancer Res. 2018;8:1551–1563.
  • Tsuda H, Yamamoto K, Inoue T, Uchiyama I, Umesaki N. The role of p16-cyclin d/CDK-pRb pathway in the tumorigenesis of endometrioid-type endometrial carcinoma. Br J Cancer. 2000;82:675–682.
  • Liang S, Mu K, Wang Y, Zhou Z, Zhang J, Sheng Y, Zhang T. CyclinD1, a prominent prognostic marker for endometrial diseases. Diagn Pathol. 2013;8:138.
  • Tanaka T, Terai Y, Ashihara K, Fujiwara S, Tanaka Y, Sasaki H, Tsunetoh S, Ohmichi M. The efficacy of the cyclin-dependent kinase 4/6 inhibitor in endometrial cancer. PLoS One. 2017;12:e0177019.
  • Ralff MD, Kline CLB, Kucukkase OC, Wagner J, Lim B, Dicker DT, Prabhu VV, Oster W, El-Deiry WS. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms. Mol Cancer Ther. 2017;16:1290–1298.
  • Gottwald L, Szwalski J, Piekarski J, Pasz-Walczak G, Kubiak R, Spych M, Suzin J, Tylinski W, Sek P, Jeziorski A. Membrane expression of the death ligand trail receptors DR4 and DR5 in the normal endometrium, endometrial atypical hyperplasia and endometrioid endometrial cancer. J Obstet Gynaecol. 2013;33:512–518.
  • Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, Villalon M, Lipkowitz S, Cuello M, Owen GI. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis. 2007;12:73–85.
  • MacKay HJ, Freixinos VR, Fleming GF. Therapeutic Targets and. Opportunities in Endometrial Cancer: update on Endocrine Therapy and Nonimmunotherapy Targeted Options. Am Soc Clin Oncol Educ Book. 2020;40:1–11.
  • Alvarez EA, Brady WE, Walker JL, Rotmensch J. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129:22–27.
  • Westin SN, Sill MW, Coleman RL, Waggoner S. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: an NRG Oncology/GOG study. Gynecol Oncol. 2019;155:420–428.
  • Zuch de Zafra CL, Ashkenazi A, Darbonne WC, Cheu M. Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L/TRAIL in the cynomolgus monkey. Cell Death Dis. 2016;7:e2338.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.